Remember
 

$IONS Ionis Pharma has initiated a Phase 1/2a clinical study of IONIS-MAPTRx in patients with mild Alzheimer's disease; co earned a $10M milestone payment from Biogen (BIIB) related to the initiation of this study.


 5 days ago by corporatealerts  •  Posted on Friday, October 13th at 5:04 AM MST  •  0 REACTIONS

React to the Post Above with Your Unique Insight
 

Global Streams

 
PulseStream
SpecStream
UserStream
EchoStream